Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Recurrence × ixazomib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Sarcoma, Kaposi 1 Recurrence 1 Genetic Diseases, Inborn 1

Interventions

Vinorelbine 4 Dexamethasone 4 Filgrastim 3 Peripheral Blood Stem Cell Transplantation 2 Granulocyte Colony-Stimulating Factor 2 Gemcitabine 2 Fenretinide 2 Etoposide 2 Carmustine 2 Bortezomib 2 zanubrutinib 1 relatlimab 1 pomalidomide 1 liposomal amphotericin B 1 ixazomib 1 irinotecan sucrosofate 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 imetelstat 1 etoposide phosphate 1 elotuzumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carfilzomib 1 auricularum 1 aldesleukin 1 Vincristine 1 Vancomycin 1 Traumeel S 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03683277 2025-02-19

IFM2014-01

Intergroupe Francophone du Myelome

Phase 2 Terminated

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon ⚡